Supply shortages and insurance hurdles for this powerful class of drugs, called GLP-1 agonists, have left many people who are suffering from diabetes and obesity without the medicines they need to stay healthy
Semaglutide was originally created to treat patients with diabetes, however, a secondary application was later found as a medicine used for weight loss, to lower blood sugar levels, and to reduce the risk of major cardiovascular events such as heart attack or stroke in type two diabetes patients
The drugs included in BALANCE: Both Novo Nordisk and Eli Lilly have agreed to participate in the model, and the following medications will be included: all formulations of Mounjaro, Ozempic, Rybelsus, and Wegovy, the KwikPen formulation of Zepbound, and, if approved by the FDA, the tablet formulation of Orforglipron
Our medically supervised approach begins with a metabolic health assessment and goal setting to personalize a plan just for you
However, nausea is a common side effect of GLP-1 therapy itself, especially during the first 48 weeks of treatment, so layering a cold illness on top of existing GLP-1 nausea can compound digestive discomfort and dehydration risk
The MR-base platform supports systematic causal inference across the human phenome